Tuebingen

• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Not authorised
  2022-500536-11-00 5 Moderately to severely active ulcerative colitis
• ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised
  2022-500537-84-00 5 Moderately to severely active ulcerative colitis
• A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into … Not authorised
  2022-501644-15-00 4 Mild Cognitive Impairment due to Alzheimer's Disease Alzheimer's Disea
• FusionVAC22_01: DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocel … Not authorised
  2022-502869-17-00 1 tumor entities carrying the oncogenic driver fusion DNAJB1-PRKACA
• A study to test a new immunotherapy, ABX-001, alone and in combination with the marketed drug, pembrolizumab, for the treatment of tumors pr … Not authorised
  2024-512403-39-00 1 Advanced Solid Tumors Who Are Beyond Standard of Care
• A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects with … Not authorised
  2024-515199-10-00 4 Retinitis Pigmentosa
• A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in part … Pending
  2024-513496-40-00 4 PARKINSON’S DISEASE
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• Long-term impact of GBCAs on motor and cognitive function following repeated Contrast-Enhanced MRI—ODYSSEY Pending
  2024-515462-14-00 6 Long term potential effect of repeated exposure to either a linear or
• Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB) Pending
  2024-517133-40-00 5 newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC ampli
• A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis (ADAPTIVE) Pending
  2024-520117-50-00 4 Atopic Dermatitis
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending
  2025-521037-86-00 5 Immune system diseases
• Extension Study of ADX-324 in Hereditary angioedema Pending
  2025-521353-16-00 5 Hereditary Angioedema
• Phase 3 trial of VMX-C001 vs usual pharmacological care in patients taking a FXa direct oral anticoagulant who require urgent surgery with o … Pending
  2025-521632-12-00 5 Patients on Factor Xa inhibitor treatment needing an urgent interventi
• A clinical trial to assess the efficacy and safety of ADX-308, a new type of treatment for Geographic Atrophy (GA), an advanced stage of eye … Pending
  2025-521779-30-00 4 Geographic atrophy secondary to age-related macular degeneration
• OTL-200 Long Term Insertional Oncogenesis Study Pending
  2025-522275-28-00 6 Metachromatic leukodystrophy
• Phase 3 Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression Pending
  2025-522748-42-00 5 Ovarian cancer
• A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending
  2025-522855-25-00 5 Urinary Bladder Neoplasms
• An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr … Pending
  2025-522983-33-00 5 Chronic rhinosinusitis with nasal polyps
• A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden … Pending
  2025-523259-72-00 5 Hidradenitis Suppurativa (HS)
• A Phase 1 Study of AIR-001 in Adults with AATD. Pending
  2025-523558-14-00 1 Alpha-1 Antitrypsin Deficiency
• A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma Pending
  2025-523815-12-00 5 Relapsed or Refractory Multiple Myeloma
• A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta … Pending
  2025-523869-22-00 5 advanced or metastatic extrapulmonary neuroendocrine carcinoma
• Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients (AugMMent) Pending
  2025-523990-40-00 5 Newly diagnosed Multiple Myeloma in patients eligible for stem cell tr

Showing 1–24 of 600 trials